Status:

COMPLETED

Effects of Enhancers and Inhibitors on Absorption From Iron Supplements

Lead Sponsor:

Swiss Federal Institute of Technology

Conditions:

Iron-deficiency

Iron Deficiency Anemia

Eligibility:

FEMALE

18-45 years

Phase:

NA

Brief Summary

Iron deficiency (ID) is a major public health problem worldwide and oral iron supplementation can be an effective strategy to treat and prevent ID. To maximize iron bioavailability form oral iron supp...

Eligibility Criteria

Inclusion

  • Female, 18 to 45 years old,
  • SF levels \<30 μg/L,
  • Body weight \< 70 kg
  • Normal Body Mass Index (18.5-25 kg/m2),
  • Signed informed consent.

Exclusion

  • Anemia (Hb \< 12 g/dL)
  • Elevated CRP \> 5 mg/L,
  • Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) affecting iron metabolism,
  • Continuous/long-term use of medication during the whole study, which may interfere with iron absorption, gut physiology and iron metabolism,
  • Consumption of mineral and vitamin supplements since screening and over the study period until last blood sample collection,
  • Difficulties with blood sampling,
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months,
  • Known hypersensitivity or allergy to iron capsules in the given amount (ferrous fumarate, brilliant blue FCF (E133), titandioxide (E171) and sodium lauryl sulfate)
  • Pregnancy, breastfeeding
  • Women who intend to become pregnant during the course of the study,
  • Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse,
  • Smokers (\> 1 cigarette per week),
  • Participant is likely to be absent on one the study appointments,
  • Inability to follow the procedures of the study, e.g. due to language problems, self-reported psychological disorders, etc. of the participant.

Key Trial Info

Start Date :

June 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 9 2022

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT05414474

Start Date

June 20 2022

End Date

December 9 2022

Last Update

January 25 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ETH Zurich; Human Nutrition Laboratory; Institute of Food, Nutrition and Health

Zurich, Switzerland, 8092